RUNX2-modifying enzymes: therapeutic targets for bone diseases

Area of Science:

• Molecular Biology
• Developmental Biology
• Genetics

Background:

• RUNX2 is a master transcription factor essential for osteoblast differentiation and cranial suture closure.
• Precise regulation of RUNX2 activity is achieved through various posttranslational modifications (PTMs).
• Dysregulation of RUNX2 or its PTM pathways leads to congenital craniofacial malformations.

Purpose of the Study:

• To review the mechanisms of RUNX2 regulation by PTMs.
• To summarize therapeutic targets related to PTM enzymes for congenital cranial suture anomalies.

Main Methods:

• Review of literature on RUNX2 posttranslational modifications.
• Analysis of genetic defects and mutations affecting RUNX2 and FGFR pathways.
• Summary of PTM enzymes and their therapeutic potential.

Main Results:

• RUNX2 PTMs include phosphorylation, prolyl isomerization, acetylation, and ubiquitination.
• Haploinsufficiency of RUNX2 causes cleidocranial dysplasia (CCD).
• Gain-of-function mutations in FGFRs lead to craniosynostosis (CS).

Conclusions:

• PTM cascades offer insights into RUNX2 regulation.
• PTM enzymes represent potential drug targets for treating craniofacial anomalies.
• Targeting RUNX2 PTMs could provide novel therapeutic strategies for skeletal disorders.